Glycerophospholipid Analysis of Optic Nerve Regeneration Models Indicate Potential Membrane Order Changes Associated with the Lipidomic Shifts
Journal of Ocular Pharmacology and Therapeutics · 2023
DOI: 10.1089/jop.2023.0003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2023. Verfasst von Sean D Meehan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bascom Palmer Eye Institute, Miller School of Medicine at University of Miami, Miami, Florida, USA. Hauptthemen laut MEDLINE: Optic Nerve, Optic Nerve Injuries. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Purpose
Optic nerve (ON) injury causes irreversible degeneration, leading to vision loss that cannot be restored with available therapeutics. Current therapies slow further degeneration but do not promote regeneration. New regenerative factors have been discovered that are successful in vivo . However, the mechanisms of efficient long-distance regeneration are still unknown. Membrane expansion by lipid insertion is an essential regenerative process, so lipid profiles for regenerating axons can provide insight into growth mechanisms. This article's analysis aims to add to the increasingly available ON regeneration lipid profiles and relate it to membrane order/properties.
Methods
In this study, we present an analysis of glycerophospholipids, one of the largest axonal lipid groups, from three mammalian ON regeneration lipid profiles: Wnt3a, Zymosan + CPT-cAMP, and Phosphatase/Tensin homolog knockout (PTENKO) at 7 and 14 days post crush (dpc). Significant lipid classes, species, and ontological properties were crossreferenced between treatments and analyzed using Metaboanalyst 5.0 and Lipid Ontology (LION). Membrane order changes associated with significant lipid classes were evaluated by C-Laurdan dye and exogenous lipids provided to a neuroblastoma cell line. Results and Conclusions: At 7 dpc, ONs show increased lysoglycerophospholipids and decreased phosphatidylethanolamines (PEs)/negative intrinsic curvature lipids. At 14 dpc, regenerative treatments show divergence: Wnt3a displays higher lysoglycerophospholipid content, while Zymosan and PTENKO decrease lysoglycerophospholipids and increase phosphatidylcholine (PC)-related species. Membrane order imaging indicates lysoglycerophospholipids decreases membrane order while PE and PC had no significant membrane order effects. Understanding these changes will allow therapeutic development targeting lipid metabolic pathways that can be used for vision loss treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bascom Palmer Eye Institute, Miller School of Medicine at University of Miami, Miami, Florida, USA.
- Miami Integrative Metabolomics Research Center, Miller School of Medicine at University of Miami, Miami, Florida, USA.
- College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, USA.
Förderung
- NEI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Meehan, S. D., Neag, E., & Bhattacharya, S. K. (2023). Glycerophospholipid Analysis of Optic Nerve Regeneration Models Indicate Potential Membrane Order Changes Associated with the Lipidomic Shifts. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2023.0003
Vancouver
Meehan SD, Neag E, Bhattacharya SK. Glycerophospholipid Analysis of Optic Nerve Regeneration Models Indicate Potential Membrane Order Changes Associated with the Lipidomic Shifts. Journal of Ocular Pharmacology and Therapeutics. 2023. doi:10.1089/jop.2023.0003
BibTeX
@article{Meehan2023,
author = {Meehan, Sean D and Neag, Emily and Bhattacharya, Sanjoy K},
title = {Glycerophospholipid Analysis of Optic Nerve Regeneration Models Indicate Potential Membrane Order Changes Associated with the Lipidomic Shifts},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2023},
doi = {10.1089/jop.2023.0003}
}
EUVIMED